Amylyx Pharmaceuticals, Inc. - Common Stock (AMLX)

Amylyx Pharmaceuticals (NASDAQ:AMLX) Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference. Klee described avexitide as a

ASA Gold and Precious Metals Limited targets global mining equities, specializing in gold, silver, and other precious minerals investments.

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares

This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.

Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.

Amylyx Pharmaceuticals (NASDAQ:AMLX) is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the third quarter, Co-Chief Executive Officer Joshua Cohen said at the BofA Annual Healthcare Conferenc

Amylyx (AMLX) Q1 2026 Earnings Transcript

Amylyx (AMLX) Q4 2025 Earnings Call Transcript

This biotech specializes in monoclonal antibody therapies for inflammatory and immunological diseases with significant unmet needs.

RAPT Therapeutics develops oral therapies for oncology and inflammatory diseases, with lead candidates progressing in clinical trials.

This clinical-stage biotech develops therapies targeting hematologic disorders, with a pipeline centered on red blood cell biology.

A Co-CEO of a leading neurotherapeutics developer reported significant insider selling amid a year of standout stock performance. But the sale is not what it seems.

A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.

Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.

A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.

One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.

A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.

This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.

A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.

One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.

Amylyx Pharmaceuticals posts a narrower-than-expected Q3 2025 loss. The company bolsters its cash position, extending its runway into 2028 to fund its clinical pipeline.

Bank of America analyst Tim Anderson raised the firm's price target on Amylyx to $14 from $10 while keeping a ‘Buy’ rating on the shares after the company reiterated earlier this week that it has a cash runway until the end of 2026.